Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jagannadha Avasarala

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Drug Target Insights|July 18, 2018
DRESS Syndrome and Daclizumab Failure-Were Potentially Dangerous Signs Missed in Clinical Trials?Jagannadha Avasarala
F1000Research|May 28, 2016
The TOUCH program and natalizumab: Fundamental flaw in patient protectionJagannadha Avasarala
Drug Target Insights|November 11, 2017
Anti-CD20 Cell Therapies in Multiple Sclerosis-A Fixed Dosing Schedule for Ocrelizumab is OverkillJagannadha Avasarala
Innovations in Clinical Neuroscience|October 6, 2017
It's Time For Combination Therapies: in Multiple SclerosisJagannadha Avasarala
Innovations in Clinical Neuroscience|June 7, 2017
Redefining Acute Relapses in Multiple Sclerosis: Implications for Phase 3 Clinical Trials and Treatment AlgorithmsJagannadha Avasarala
Diagnosis (Berlin, Germany)|November 17, 2025
Transatlantic confusion in MS diagnostic criteria: one patient, two continents, zero diagnosisJagannadha Avasarala
Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association|October 16, 2025
Dark chocolate, heavy metals, and neurodevelopment in childrenJagannadha Avasarala
CNS Spectrums|January 4, 2019
FDA-approved drugs for multiple sclerosis have no efficacy or disability data in non-Caucasian patientsJagannadha Avasarala
Frontiers in Neurology|August 24, 2018
Can Aspirin Minimize Stroke Risk and New Lesion Formation in Multiple Sclerosis?Jagannadha Avasarala, Naveen Parti
CNS Spectrums|July 16, 2019
Radiologically isolated syndrome is antiquated amidst evolving McDonald criteria for multiple sclerosisJagannadha Avasarala, Fawad Yousuf
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Drug Target Insights|July 18, 2018
DRESS Syndrome and Daclizumab Failure-Were Potentially Dangerous Signs Missed in Clinical Trials?Jagannadha Avasarala
F1000Research|May 28, 2016
The TOUCH program and natalizumab: Fundamental flaw in patient protectionJagannadha Avasarala
Drug Target Insights|November 11, 2017
Anti-CD20 Cell Therapies in Multiple Sclerosis-A Fixed Dosing Schedule for Ocrelizumab is OverkillJagannadha Avasarala
Innovations in Clinical Neuroscience|October 6, 2017
It's Time For Combination Therapies: in Multiple SclerosisJagannadha Avasarala
Innovations in Clinical Neuroscience|June 7, 2017
Redefining Acute Relapses in Multiple Sclerosis: Implications for Phase 3 Clinical Trials and Treatment AlgorithmsJagannadha Avasarala
Diagnosis (Berlin, Germany)|November 17, 2025
Transatlantic confusion in MS diagnostic criteria: one patient, two continents, zero diagnosisJagannadha Avasarala
Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association|October 16, 2025
Dark chocolate, heavy metals, and neurodevelopment in childrenJagannadha Avasarala
CNS Spectrums|January 4, 2019
FDA-approved drugs for multiple sclerosis have no efficacy or disability data in non-Caucasian patientsJagannadha Avasarala
Frontiers in Neurology|August 24, 2018
Can Aspirin Minimize Stroke Risk and New Lesion Formation in Multiple Sclerosis?Jagannadha Avasarala, Naveen Parti
CNS Spectrums|July 16, 2019
Radiologically isolated syndrome is antiquated amidst evolving McDonald criteria for multiple sclerosisJagannadha Avasarala, Fawad Yousuf
Pageof 3